Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.
Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases. The award also recognized the company’s track record on access to drugs and its collaboration with patient organizations.
EURORDIS is Europe’s largest patient organization in rare diseases. Its CEO, Yann Le Camm, commented: “We are honored to acknowledge the commitment and achievements of the recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2014.” This year, he added, Rare Disease Day puts the spotlight on care.
Sobi’s CEO, Geoffrey McDonough, said: “We are inspired to pioneer a world in which rare disease patients are diagnosed at birth,receive effective and sustainable therapy, and go on to live full and healthy lives.”
Other winners at the EURORDIS AWards included Orphan Europe, part of the Recordati group, which has nearly 25 years’ experience in bringing orphan drugs to market for rare diseases with seven products to date.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.